ConductScience.org, home

Paper39028129

Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review.

Zhang K and 6 others. World J Mens Health, 2025. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review. Papers, record 39028129. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39028129

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review.
PubMed
Journal
World J Mens Health
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
4.0, provisional
iCite
Revised in PubMed
2025-04-02
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135123819Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience.Eur Urol2022https://conductscience.org/library/papers/35123819PubMed
233782057The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ2021https://conductscience.org/library/papers/33782057PubMed
335789204The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.Nat Rev Urol2022https://conductscience.org/library/papers/35789204PubMed
431725935Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.BJU Int2020https://conductscience.org/library/papers/31725935PubMed
525179590Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.Prostate Cancer Prostatic Dis2014https://conductscience.org/library/papers/25179590PubMed
631103721Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.Eur Urol Oncol2020https://conductscience.org/library/papers/31103721PubMed
727697580Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.J Urol2017https://conductscience.org/library/papers/27697580PubMed
830768957Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome.Magn Reson Imaging2019https://conductscience.org/library/papers/30768957PubMed
936441776
A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
J Urol2023https://conductscience.org/library/papers/36441776PubMed
1030638633Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.Eur Urol2019https://conductscience.org/library/papers/30638633PubMed
1130385049Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.Eur Urol2019https://conductscience.org/library/papers/30385049PubMed
1228796935Focal irreversible electroporation as primary treatment for localized prostate cancer.BJU Int2018https://conductscience.org/library/papers/28796935PubMed
1330211680Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments.Diagn Interv Radiol2018https://conductscience.org/library/papers/30211680PubMed
1436073928Focal Therapy of Prostate Cancer Index Lesion With Irreversible Electroporation. A Prospective Study With a Median Follow-up of 3 Years.J Urol2023https://conductscience.org/library/papers/36073928PubMed
1532488359Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).World J Urol2021https://conductscience.org/library/papers/32488359PubMed
1630986263Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.PLoS One2019https://conductscience.org/library/papers/30986263PubMed
1732209449Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.Lancet2020https://conductscience.org/library/papers/32209449PubMed
1826296371The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients.World J Urol2016https://conductscience.org/library/papers/26296371PubMed
1935793110Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial.JAMA Surg2022https://conductscience.org/library/papers/35793110PubMed
2036910902Irreversible electroporation for prostate cancer using PSMA PET-CT.Prostate Int2023https://conductscience.org/library/papers/36910902PubMed

See all 38 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42755971Functional outcomes and biochemical control after radical prostatectomy versus irreversible electroporation for localized prostate cancer.iScience2026https://conductscience.org/library/papers/42755971PubMed
42614700Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomater Res2026https://conductscience.org/library/papers/42614700PubMed
42382550Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.Prostate Int2026https://conductscience.org/library/papers/42382550PubMed
42192883Focal Therapy for Prostate Cancer: State of the Art, Physical Principles, Potentials, and Challenges.Cancers (Basel)2026https://conductscience.org/library/papers/42192883PubMed
42099853Magnetic resonance imaging/ultrasound fusion-guided targeted biopsy and ultrasound-guided systematic biopsy for prior negative prostate biopsy: A meta-analysis.Indian J Urol2026https://conductscience.org/library/papers/42099853PubMed
40647385Oncological and Functional Outcomes of Hemi-Ablation Versus Focal Ablation for Localized Prostate Cancer Using Irreversible Electroporation.Cancers (Basel)2025https://conductscience.org/library/papers/40647385PubMed
40385365Extraprostatic Needle Canal Recurrence of Localized Prostate Cancer After Nanoknife Electroporation Ablation Diagnosed with PSMA PET/MRI.Nucl Med Mol Imaging2025https://conductscience.org/library/papers/40385365PubMed
40117314Active matter as the underpinning agency for extraordinary sensitivity of biological membranes to electric fields.Proc Natl Acad Sci U S A2025https://conductscience.org/library/papers/40117314PubMed
39623055Salvage irreversible electroporation for locally recurrent prostate cancer after definitive radiotherapy: a systematic review.Prostate Cancer Prostatic Dis2025https://conductscience.org/library/papers/39623055PubMed
39589586Advances in irreversible electroporation for prostate cancer.Discov Oncol2024https://conductscience.org/library/papers/39589586PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39028129

GET https://conductscience.org/api/papers/v1/39028129/references?page=2